Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 8/20 | 0.42 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4663154 | 0.86 | PTGER1 (0.40) | PTGER1KDM1APTPN1MAOBSLC6A4 | |
| SCHEMBL4662895 | 0.73 | MEN1 (0.46) | PTGER1KDM1AMAOBSLC6A4CYP1A2 | |
| SCHEMBL30501926 | 0.71 | TNF (0.47) | PTGER1CYP1A2 | |
| SCHEMBL4664727 | 0.71 | DRD4 (0.53) | PTGER1KDM1APTPN1MAOBSLC6A4 | |
| SCHEMBL4664771 | 0.71 | RHEB (0.48) | PTGER1KDM1AMAOBSLC6A4 | |
| SCHEMBL18372654 | 0.71 | TNF (0.47) | PTGER1CYP1A2 | |
| SCHEMBL4663138 | 0.71 | GCK (0.45) | KDM1AMAOBSLC6A4 | |
| SCHEMBL34475846 | 0.70 | MAOB (0.43) | PTGER1KDM1AMAOBSLC6A4CYP1A2 | |
| SCHEMBL4664857 | 0.70 | GCK (0.40) | PTGER1MAOBSLC6A4CYP1A2 | |
| SCHEMBL4664610 | 0.69 | BRD4 (0.47) | MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113963-A1 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2008-05-15 | — | — | US | disclosed |
| US-7307084-B2 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2007-12-11 | — | — | US | disclosed |
| US-20060194968-A1 | Cyclic benizimidazoles | ALTANA PHARMA AG (DE) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194968-A1 | Cyclic benizimidazoles | VIP, SI, GIPR | PTGER1 308/4885KDM1A 1161/4885PTPN1 3353/4885 |
| US-20080113963-A1 | Cyclic benzimidazoles | VIP, GIPR, SI | PTGER1 2767/4885KDM1A 3988/4885PTPN1 4681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.